Difference between revisions of "Haloperidol-Haloperidol LA"
From Psychiatrienet
(Created page with '{{Drugswitch | from = Haloperidol | to = Haloperidol_LA | stop = {{Downslweeks}} | start = {{StartDepot}} | view = | info = }}') |
(No difference)
|
Revision as of 10:46, 14 August 2009
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
Switch medication from Haloperidol to Haloperidol_LA.[6] [7]
Stop Haloperidol - Week 1-3: approx. 75% of initial dose
- Week 4-6: approx. 50% of initial dose
- Week 7-9: approx. 25% of initial dose
- Week 10: stop
Start Haloperidol_LA- Day 1: Start depot according general dosing advice (Dotted line in graph)
- ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
- ↑ 2.0 2.1 2.2 KNMP; Informatorium Medicamentorum 2023; Monografie "haloperidol" (Dutch)
- ↑ 3.0 3.1 3.2 3.3 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
- ↑ 4.0 4.1 4.2 4.3 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
- ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
